Clinical Trial Challenges Amid COVID-19
Summary: Due to the influx of COVID-19 related therapies being expedited into clinical testing, studies in other areas are either proceeding with heightened caution or are essentially being put on the backburner. It is reasonable to anticipate that this decreased R&D activity will likely have a significant impact on the drug development pipeline—but to what extent?
This webinar hosted by Fierce Pharma is introduced by Ricci Whitlow, President of Clinical Supply Services at Catalent.